Skip to main content
رجوع
Watch Compare

Carisma Therapeutics Inc.

جودة البيانات: 100%
CARM
OTC Manufacturing Chemicals
KWD 0.03
▲ KWD 0.00 (3.23%)
القيمة السوقية: 1.34 M
السعر
KWD 0.03
القيمة السوقية
1.34 M
نطاق اليوم
KWD 0.03 — KWD 0.03
نطاق 52 أسبوعًا
KWD 0.03 — KWD 1.27
حجم التداول
2,100
فتح KWD 0.03
متوسط 50 يوم / 200 يوم
KWD 0.04
18.16% below
متوسط 50 يوم / 200 يوم
KWD 0.16
79.90% below

Quick Summary

النقاط الرئيسية

Net margin of 15.29% shows strong profitability
Negative free cash flow of -22.42 M
P/E of 0.17 — trading at a low valuation
Capital efficient — spends only 0.00% of revenue on capex

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)31.54%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
N/A
ROICN/A
Net Margin15.29%
Op. Margin20.62%

الأمان

Debt / Equity
N/A
Current Ratio0.86
Interest CoverageN/A

التقييم

PE (TTM)
0.17
أعلى من متوسط القطاع (-1.47)
P/B RatioN/A
EV/EBITDA-0.12
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1364 نظير)
المقياس السهم وسيط القطاع
P/E 0.2 -1.5
P/B — 1.6
ROE % — -53.5
Net Margin % 15.3 -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

ETFs Holding This Stock

IRGSX IRGSX
0.38% weight
IRGIX IRGIX
0.38% weight
AVRE logo AVRE Avantis Real Estate ETF
0.17% weight
VGSR logo VGSR Vert Global Sustainable Real Estate ETF
0.13% weight
HAUZ logo HAUZ Xtrackers International Real Estate ETF
0.11% weight
WMRIX WMRIX
0.03% weight
WMMRX WMMRX
0.03% weight
DBEZ logo DBEZ Xtrackers MSCI Eurozone Hedged Equity ETF
0.02% weight
GTPE logo GTPE Goldman Sachs MSCI World Private Equity Return Tracker ETF
0.01% weight
NARCX NARCX
0.01% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) 31.54% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 52.60 M Net Income (TTM) 8.04 M
ROE N/A ROA 139.06%
Gross Margin N/A Operating Margin 20.62%
Net Margin 15.29% Free Cash Flow (TTM) -22.42 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0.86
Interest Coverage N/A Asset Turnover 9.10
Working Capital -942,000 Tangible Book Value -867,000
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 0.17 Forward P/E N/A
P/B Ratio N/A P/S Ratio 0.03
PEG Ratio N/A Forward PEG N/A
EV/EBITDA -0.12 Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -1673.96%
Market Cap 1.34 M Enterprise Value -1.44 M
Per Share
EPS (Diluted TTM) 0.19 Revenue / Share 1.26
FCF / Share -0.54 OCF / Share -0.54
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0.00% FCF Conversion -278.72%
SBC-Adj. FCF -24.89 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 19.60 M 14.90 M — — —
Net Income -60.48 M -86.88 M -19.88 M -336,000.0 -22.40 M
EPS (Diluted) -1.46 -2.59 -0.10 0.00 —
Gross Profit — — — — —
Operating Income -62.18 M -88.73 M -25.91 M -8.55 M -21.08 M
EBITDA — — — — —
R&D Expenses 59.67 M 74.13 M 38.59 M 25.31 M 29.19 M
SG&A Expenses — — — — —
D&A 3.35 M 2.84 M 13,000.0 85,000.0 122,000.0
Interest Expense — — — — —
Income Tax — — -3.88 M -8.27 M 1.45 M

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 30.46 M 89.55 M 189.17 M 240.75 M 122.82 M
Total Liabilities 58.37 M 63.02 M 30.98 M 69.04 M 132.05 M
Shareholders' Equity -27.91 M 26.53 M 158.19 M 171.71 M -9.23 M
Total Debt — — — — —
Cash & Equivalents 17.91 M 77.61 M 112.55 M 162.64 M 52.39 M
Current Assets 23.83 M 80.47 M 189.14 M 205.61 M 62.87 M
Current Liabilities 16.06 M 15.91 M 30.98 M 11.57 M 18.05 M